{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:21:30Z","timestamp":1791264090550,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/nm.3184","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T18:28:09Z","timestamp":1373308089000},"page":"850-858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":243,"title":["Global control of hepatitis C: where challenge meets opportunity"],"prefix":"10.1038","volume":"19","author":[{"given":"David L","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,8]]},"reference":[{"key":"BFnm3184_CR1","doi-asserted-by":"publisher","first-page":"15S","DOI":"10.1002\/hep.510260703","volume":"26","author":"JH Hoofnagle","year":"1997","unstructured":"Hoofnagle, J.H. & Hepatitis, C. The clinical spectrum of disease. Hepatology 26, 15S\u201320S (1997).","journal-title":"Hepatology"},{"key":"BFnm3184_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/hep.510290311","volume":"29","author":"SA Villano","year":"1999","unstructured":"Villano, S.A. et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29, 908\u2013914 (1999).","journal-title":"Hepatology"},{"key":"BFnm3184_CR3","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1086\/428578","volume":"40","author":"AL Cox","year":"2005","unstructured":"Cox, A.L. et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin. Infect. Dis. 40, 951\u2013958 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"BFnm3184_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/hep.20742","volume":"42","author":"JW Mosley","year":"2005","unstructured":"Mosley, J.W. et al. Viral and host factors in early hepatitis C virus infection. Hepatology 42, 86\u201392 (2005).","journal-title":"Hepatology"},{"key":"BFnm3184_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee, M.H. et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J. Infect. Dis. 206, 469\u2013477 (2012).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/hep.510250344","volume":"25","author":"S Bruno","year":"1997","unstructured":"Bruno, S. et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 25, 754\u2013758 (1997).","journal-title":"Hepatology"},{"key":"BFnm3184_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","volume":"9","author":"DL Thomas","year":"2005","unstructured":"Thomas, D.L. & Seeff, L.B. Natural history of hepatitis C. Clin. Liver Dis. 9, 383\u2013398 (2005).","journal-title":"Clin. Liver Dis."},{"key":"BFnm3184_CR8","first-page":"1584","volume":"100","author":"JJ Goedert","year":"2002","unstructured":"Goedert, J.J. et al. End-stage liver disease in persons with hemophilia and transfusion- associated infections. Blood 100, 1584\u20131589 (2002).","journal-title":"Blood"},{"key":"BFnm3184_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jama.284.4.450","volume":"284","author":"DL Thomas","year":"2000","unstructured":"Thomas, D.L. et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. J. Am. Med. Assoc. 284, 450\u2013456 (2000).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnm3184_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard, T., Bedossa, P. & Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349, 825\u2013832 (1997).","journal-title":"Lancet"},{"key":"BFnm3184_CR11","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/hep.1840140603","volume":"14","author":"AM Di Bisceglie","year":"1991","unstructured":"Di Bisceglie, A.M. et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 14, 969\u2013974 (1991).","journal-title":"Hepatology"},{"key":"BFnm3184_CR12","doi-asserted-by":"publisher","first-page":"14562","DOI":"10.1073\/pnas.1210592109","volume":"109","author":"P Farci","year":"2012","unstructured":"Farci, P. et al. Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc. Natl. Acad. Sci. USA 109, 14562\u201314567 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3184_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1086\/590430","volume":"198","author":"DS Fierer","year":"2008","unstructured":"Fierer, D.S. et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J. Infect. Dis. 198, 683\u2013686 (2008).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR14","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","volume":"327","author":"V Agnello","year":"1992","unstructured":"Agnello, V., Chung, R.T. & Kaplan, L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med. 327, 1490\u20131495 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","volume":"133","author":"SH Mehta","year":"2000","unstructured":"Mehta, S.H. et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med. 133, 592\u2013599 (2000).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/hep.20659","volume":"41","author":"BM Spiegel","year":"2005","unstructured":"Spiegel, B.M. et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41, 790\u2013800 (2005).","journal-title":"Hepatology"},{"key":"BFnm3184_CR17","first-page":"121","volume":"2","author":"S Conrad","year":"2006","unstructured":"Conrad, S. et al. Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illn. 2, 121\u2013131 (2006).","journal-title":"Chronic Illn."},{"key":"BFnm3184_CR18","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1001\/archinte.161.18.2231","volume":"161","author":"JP Leigh","year":"2001","unstructured":"Leigh, J.P. et al. Costs of hepatitis C. Arch. Intern. Med. 161, 2231\u20132237 (2001).","journal-title":"Arch. Intern. Med."},{"key":"BFnm3184_CR19","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","volume":"45","author":"KL Davis","year":"2011","unstructured":"Davis, K.L. et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J. Clin. Gastroenterol. 45, e17\u2013e24 (2011).","journal-title":"J. Clin. Gastroenterol."},{"key":"BFnm3184_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","volume":"156","author":"DB Rein","year":"2012","unstructured":"Rein, D.B. et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann. Intern. Med. 156, 263\u2013270 (2012).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","volume":"156","author":"S Liu","year":"2012","unstructured":"Liu, S. et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann. Intern. Med. 156, 279\u2013290 (2012).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/(SICI)1096-9071(199703)51:3<231::AID-JMV15>3.0.CO;2-N","volume":"51","author":"I Mendel","year":"1997","unstructured":"Mendel, I. et al. Detection and genotyping of the hepatitis C RNA in tear fluid from patients with chronic hepatitis C. J. Med. Virol. 51, 231\u2013233 (1997).","journal-title":"J. Med. Virol."},{"key":"BFnm3184_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.7326\/0003-4819-115-6-443","volume":"115","author":"JI Esteban","year":"1991","unstructured":"Esteban, J.I. et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann. Intern. Med. 115, 443\u2013449 (1991).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.7326\/0003-4819-115-5-411_1","volume":"115","author":"LB Seeff","year":"1991","unstructured":"Seeff, L.B. Hepatitis C from a needlestick injury. Ann. Intern. Med. 115, 411 (1991).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/bmj.315.7104.333","volume":"315","author":"GJ Dore","year":"1997","unstructured":"Dore, G.J., Kaldor, J.M. & McCaughan, G.W. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. Br. Med. J. 315, 333\u2013337 (1997).","journal-title":"Br. Med. J."},{"key":"BFnm3184_CR26","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1086\/515315","volume":"177","author":"DL Thomas","year":"1998","unstructured":"Thomas, D.L. et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. J. Infect. Dis. 177, 1480\u20131488 (1998).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR27","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1086\/497701","volume":"192","author":"EE Mast","year":"2005","unstructured":"Mast, E.E. et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J. Infect. Dis. 192, 1880\u20131889 (2005).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0140-6736(95)90277-5","volume":"345","author":"AR Zanetti","year":"1995","unstructured":"Zanetti, A.R. et al. Mother-to-infant transmission of hepatitis C virus. Lancet 345, 289\u2013291 (1995).","journal-title":"Lancet"},{"key":"BFnm3184_CR29","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1086\/656212","volume":"202","author":"E Paintsil","year":"2010","unstructured":"Paintsil, E. et al. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J. Infect. Dis. 202, 984\u2013990 (2010).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/infdis\/jis677","volume":"207","author":"J Doerrbecker","year":"2013","unstructured":"Doerrbecker, J. et al. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J. Infect. Dis. 207, 281\u2013287 (2013).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/00365549309008497","volume":"25","author":"M Sartori","year":"1993","unstructured":"Sartori, M. et al. Transmission of hepatitis C via blood splash into conjunctiva. Scand. J. Infect. Dis. 25, 270\u2013271 (1993).","journal-title":"Scand. J. Infect. Dis."},{"key":"BFnm3184_CR32","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/infdis\/171.4.768","volume":"171","author":"DL Thomas","year":"1995","unstructured":"Thomas, D.L. et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships. J. Infect. Dis. 171, 768\u2013775 (1995).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR33","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJM199606273342602","volume":"334","author":"C Conry-Cantilena","year":"1996","unstructured":"Conry-Cantilena, C. et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med. 334, 1691\u20131696 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR34","doi-asserted-by":"publisher","first-page":"748","DOI":"10.7326\/0003-4819-120-9-199405010-00005","volume":"120","author":"Y Akahane","year":"1994","unstructured":"Akahane, Y. et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann. Intern. Med. 120, 748\u2013752 (1994).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/OLQ.0b013e3181ec9de5","volume":"38","author":"TJ van de Laar","year":"2011","unstructured":"van de Laar, T.J. et al. Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. Sex. Transm. Dis. 38, 102\u2013104 (2011).","journal-title":"Sex. Transm. Dis."},{"key":"BFnm3184_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/hep.26164","volume":"57","author":"NA Terrault","year":"2013","unstructured":"Terrault, N.A. et al. Sexual transmission of HCV among monogamous heterosexual couples: the HCV partners study. Hepatology 57, 881\u2013889 (2013).","journal-title":"Hepatology"},{"key":"BFnm3184_CR37","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1572-0241.2004.04150.x","volume":"99","author":"C Vandelli","year":"2004","unstructured":"Vandelli, C. et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am. J. Gastroenterol. 99, 855\u2013859 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnm3184_CR38","doi-asserted-by":"publisher","first-page":"e1002876","DOI":"10.1371\/journal.pcbi.1002876","volume":"9","author":"G Magiorkinis","year":"2013","unstructured":"Magiorkinis, G. et al. Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput. Biol. 9, e1002876 (2013).","journal-title":"PLoS Comput. Biol."},{"key":"BFnm3184_CR39","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/archinternmed.2010.511","volume":"171","author":"IT Williams","year":"2011","unstructured":"Williams, I.T. et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982\u20132006. Arch. Intern. Med. 171, 242\u2013248 (2011).","journal-title":"Arch. Intern. Med."},{"key":"BFnm3184_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/01.ede.0000135170.54913.9d","volume":"15","author":"H Hagan","year":"2004","unstructured":"Hagan, H., Thiede, H. & Des Jarlais, D.C. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 15, 543\u2013549 (2004).","journal-title":"Epidemiology"},{"key":"BFnm3184_CR41","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJM199606273342601","volume":"334","author":"GB Schreiber","year":"1996","unstructured":"Schreiber, G.B. et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N. Engl. J. Med. 334, 1685\u20131690 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-150-1-200901060-00007","volume":"150","author":"ND Thompson","year":"2009","unstructured":"Thompson, N.D. et al. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998\u20132008. Ann. Intern. Med. 150, 33\u201339 (2009).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2007.07.031","volume":"48","author":"E Mart\u00ednez-Bauer","year":"2008","unstructured":"Mart\u00ednez-Bauer, E. et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J. Hepatol. 48, 20\u201327 (2008).","journal-title":"J. Hepatol."},{"key":"BFnm3184_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1258\/095646204322637182","volume":"15","author":"AM Hauri","year":"2004","unstructured":"Hauri, A.M., Armstrong, G.L. & Hutin, Y.J. The global burden of disease attributable to contaminated injections given in health care settings. Int. J. STD AIDS 15, 7\u201316 (2004).","journal-title":"Int. J. STD AIDS"},{"key":"BFnm3184_CR45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/jmv.1890380411","volume":"38","author":"YC Ko","year":"1992","unstructured":"Ko, Y.C. et al. Tattooing as a risk of hepatitis C virus infection. J. Med. Virol. 38, 288\u2013291 (1992).","journal-title":"J. Med. Virol."},{"key":"BFnm3184_CR46","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah, K., Groeger, J., Flaxman, A.D. & Wiersma, S.T. et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology 57, 1333\u20131342 (2013).","journal-title":"Hepatology"},{"key":"BFnm3184_CR47","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","volume":"355","author":"C Frank","year":"2000","unstructured":"Frank, C. et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355, 887\u2013891 (2000).","journal-title":"Lancet"},{"key":"BFnm3184_CR48","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/hep.21173","volume":"43","author":"GT Strickland","year":"2006","unstructured":"Strickland, G.T. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 43, 915\u2013922 (2006).","journal-title":"Hepatology"},{"key":"BFnm3184_CR49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.dld.2012.10.014","volume":"45","author":"V Guadagnino","year":"2013","unstructured":"Guadagnino, V. et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. Dig. Liver Dis. 45, 403\u2013407 (2013).","journal-title":"Dig. Liver Dis."},{"key":"BFnm3184_CR50","first-page":"794","volume":"90","author":"J Hayashi","year":"1995","unstructured":"Hayashi, J. et al. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am. J. Gastroenterol. 90, 794\u2013799 (1995).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnm3184_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","volume":"144","author":"GL Armstrong","year":"2006","unstructured":"Armstrong, G.L. et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144, 705\u2013714 (2006).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0033-3506(02)00009-4","volume":"117","author":"J Baillargeon","year":"2003","unstructured":"Baillargeon, J. et al. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health 117, 43\u201348 (2003).","journal-title":"Public Health"},{"key":"BFnm3184_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","volume":"74","author":"DL Thomas","year":"1995","unstructured":"Thomas, D.L. et al. Correlates of hepatitis C virus infections among injection drug users in Baltimore. Medicine 74, 212\u2013220 (1995).","journal-title":"Medicine"},{"key":"BFnm3184_CR54","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz, J.F. et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45, 529\u2013538 (2006).","journal-title":"J. Hepatol."},{"key":"BFnm3184_CR55","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095\u20132128 (2012).","journal-title":"Lancet"},{"key":"BFnm3184_CR56","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","volume":"138","author":"GL Davis","year":"2010","unstructured":"Davis, G.L. et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138, 513\u2013521 (2010).","journal-title":"Gastroenterology"},{"key":"BFnm3184_CR57","doi-asserted-by":"publisher","first-page":"e34779","DOI":"10.1371\/journal.pone.0034779","volume":"7","author":"SF Liao","year":"2012","unstructured":"Liao, S.F. et al. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS ONE 7, e34779 (2012).","journal-title":"PLoS ONE"},{"key":"BFnm3184_CR58","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag, H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264\u20131273 (2012).","journal-title":"Gastroenterology"},{"key":"BFnm3184_CR59","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1053\/j.gastro.2006.01.032","volume":"130","author":"Y Tanaka","year":"2006","unstructured":"Tanaka, Y. et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 130, 703\u2013714 (2006).","journal-title":"Gastroenterology"},{"key":"BFnm3184_CR60","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJM199606273342601","volume":"334","author":"GB Schreiber","year":"1996","unstructured":"Schreiber, G.B. et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N. Engl. J. Med. 334, 1685\u20131690 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR61","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/infdis\/jiq112","volume":"203","author":"SH Mehta","year":"2011","unstructured":"Mehta, S.H. et al. Changes in blood-borne infection risk among injection drug users. J. Infect. Dis. 203, 587\u2013594 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR62","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison, J.G. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339, 1485\u20131492 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR63","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns, M.P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958\u2013965 (2001).","journal-title":"Lancet"},{"key":"BFnm3184_CR64","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried, M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975\u2013982 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR65","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad, F. et al. Boceprevir for intreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195\u20131206 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR66","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson, I.M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405\u20132416 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR67","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison, J.G. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580\u2013593 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR68","doi-asserted-by":"publisher","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","volume":"132","author":"Y Shiratori","year":"2000","unstructured":"Shiratori, Y. et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 132, 517\u2013524 (2000).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR69","doi-asserted-by":"publisher","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","volume":"147","author":"BJ Veldt","year":"2007","unstructured":"Veldt, B.J. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 147, 677\u2013684 (2007).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR70","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso, A.C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J. Hepatol. 52, 652\u2013657 (2010).","journal-title":"J. Hepatol."},{"key":"BFnm3184_CR71","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/hep.23020","volume":"50","author":"J Berenguer","year":"2009","unstructured":"Berenguer, J. et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50, 407\u2013413 (2009).","journal-title":"Hepatology"},{"key":"BFnm3184_CR72","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer, A.J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. J. Am. Med. Assoc. 308, 2584\u20132593 (2012).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnm3184_CR73","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","volume":"9","author":"LI Backus","year":"2011","unstructured":"Backus, L.I. et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin. Gastroenterol. Hepatol. 9, 509\u2013516 (2011).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnm3184_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7326\/0003-4819-158-2-201301150-00574","volume":"158","author":"R Chou","year":"2013","unstructured":"Chou, R. et al. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 158, 101\u2013108 (2013).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR75","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1053\/jhep.2002.31311","volume":"35","author":"D Bernstein","year":"2002","unstructured":"Bernstein, D. et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 35, 704\u2013708 (2002).","journal-title":"Hepatology"},{"key":"BFnm3184_CR76","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1038\/ajg.2009.346","volume":"104","author":"AA John-Baptiste","year":"2009","unstructured":"John-Baptiste, A.A. et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am. J. Gastroenterol. 104, 2439\u20132448 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnm3184_CR77","doi-asserted-by":"publisher","first-page":"aaa","DOI":"10.1038\/nm.3183","volume":"19","author":"J Liang","year":"2013","unstructured":"Liang, J. Nat. Med. 19, aaa\u2013bbb (2013).","journal-title":"Nat. Med."},{"key":"BFnm3184_CR78","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.296.16.2005","volume":"296","author":"PR Patel","year":"2006","unstructured":"Patel, P.R. et al. Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. J. Am. Med. Assoc. 296, 2005\u20132011 (2006).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnm3184_CR79","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1086\/649783","volume":"201","author":"H Hagan","year":"2010","unstructured":"Hagan, H. et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J. Infect. Dis. 201, 378\u2013385 (2010).","journal-title":"J. Infect. Dis."},{"key":"BFnm3184_CR80","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2105\/AJPH.85.11.1531","volume":"85","author":"H Hagan","year":"1995","unstructured":"Hagan, H. et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am. J. Public Health 85, 1531\u20131537 (1995).","journal-title":"Am. J. Public Health"},{"key":"BFnm3184_CR81","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1053\/j.gastro.2009.02.006","volume":"136","author":"T van de Laar","year":"2009","unstructured":"van de Laar, T. et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 136, 1609\u20131617 (2009).","journal-title":"Gastroenterology"},{"key":"BFnm3184_CR82","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/j.1440-1746.2010.06238.x","volume":"25","author":"J Grebely","year":"2010","unstructured":"Grebely, J. et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J. Gastroenterol. Hepatol. 25, 1281\u20131284 (2010).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFnm3184_CR83","doi-asserted-by":"publisher","first-page":"109","DOI":"10.7326\/0003-4819-158-2-201301150-00575","volume":"158","author":"EB Cottrell","year":"2013","unstructured":"Cottrell, E.B., Chou, R., Wasson, N., Rahman, B. & Guise, J.-M. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 158, 109\u2013113 (2013).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR84","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/hep.25556","volume":"55","author":"MM Denniston","year":"2012","unstructured":"Denniston, M.M. et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001\u20132008. Hepatology 55, 1652\u20131661 (2012).","journal-title":"Hepatology"},{"key":"BFnm3184_CR85","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jhep.2008.04.021","volume":"49","author":"B Lettmeier","year":"2008","unstructured":"Lettmeier, B. et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J. Hepatol. 49, 528\u2013536 (2008).","journal-title":"J. Hepatol."},{"key":"BFnm3184_CR86","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/hep.23220","volume":"50","author":"ML Volk","year":"2009","unstructured":"Volk, M.L. et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50, 1750\u20131755 (2009).","journal-title":"Hepatology"},{"key":"BFnm3184_CR87","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2011.05.032","volume":"56","author":"JR Kramer","year":"2012","unstructured":"Kramer, J.R. et al. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J. Hepatol. 56, 320\u2013325 (2012).","journal-title":"J. Hepatol."},{"key":"BFnm3184_CR88","doi-asserted-by":"publisher","first-page":"558","DOI":"10.7326\/0003-4819-157-8-201210160-00006","volume":"157","author":"S Shivkumar","year":"2012","unstructured":"Shivkumar, S. et al. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann. Intern. Med. 157, 558\u2013566 (2012).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR89","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-157-9-201211060-00529","volume":"157","author":"BD Smith","year":"2012","unstructured":"Smith, B.D. et al. Hepatitis C virus testing of persons born during 1945 to 1965: recommendations from the Centers for Disease Control and Prevention. Ann. Intern. Med. 157, 817\u2013822 (2012).","journal-title":"Ann. Intern. Med."},{"key":"BFnm3184_CR90","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok, A.S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216\u2013224 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1208809","volume":"368","author":"F Poordad","year":"2013","unstructured":"Poordad, F. et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med. 368, 45\u201353 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR92","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa1208953","volume":"368","author":"EJ Gane","year":"2013","unstructured":"Gane, E.J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34\u201344 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3184_CR93","unstructured":"Sulkowski, M.S. et al. High rate of sustained virologic response with the all-oral combination of daclatasvir plus sofosbuvir, with or without ribavirin in treatment-na\u00efve patients chronically infected with genotypes 1, 2, or 3 http:\/\/www.natap.org\/2012\/AASLD\/AASLD_06.htm (2012)."},{"key":"BFnm3184_CR94","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1038\/474S18a","volume":"474","author":"BR Edlin","year":"2011","unstructured":"Edlin, B.R. Perspective: test and treat this silent killer. Nature 474, S18\u2013S19 (2011).","journal-title":"Nature"},{"issue":"suppl. 4","key":"BFnm3184_CR95","doi-asserted-by":"publisher","first-page":"D70","DOI":"10.1016\/j.vaccine.2011.04.006","volume":"29","author":"WR Dowdle","year":"2011","unstructured":"Dowdle, W.R. & Cochi, S.L. The principles and feasibility of disease eradication. Vaccine 29 (suppl. 4), D70\u2013D73 (2011).","journal-title":"Vaccine"},{"key":"BFnm3184_CR96","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.dld.2010.05.006","volume":"43","author":"DB Rein","year":"2011","unstructured":"Rein, D.B. . et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig. Liver Dis. 43, 66\u201372 (2011).","journal-title":"Dig. Liver Dis."},{"key":"BFnm3184_CR97","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.2105\/AJPH.90.10.1562","volume":"90","author":"JB Wong","year":"2000","unstructured":"Wong, J.B. et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health 90, 1562\u20131569 (2000).","journal-title":"Am. J. Public Health"},{"key":"BFnm3184_CR98","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1365-2893.2009.01115.x","volume":"16","author":"EM Lehman","year":"2009","unstructured":"Lehman, E.M. & Wilson, M.L. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. J. Viral Hepat. 16, 650\u2013658 (2009).","journal-title":"J. Viral Hepat."},{"key":"BFnm3184_CR99","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/hep.510290528","volume":"29","author":"S Deuffic","year":"1999","unstructured":"Deuffic, S. et al. Modeling the hepatitis C virus epidemic in France. Hepatology 29, 1596\u20131601 (1999).","journal-title":"Hepatology"},{"key":"BFnm3184_CR100","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/00365540903095358","volume":"41","author":"A Mariano","year":"2009","unstructured":"Mariano, A. et al. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand. J. Infect. Dis. 41, 689\u2013699 (2009).","journal-title":"Scand. J. Infect. Dis."},{"key":"BFnm3184_CR101","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1073\/pnas.0408707102","volume":"102","author":"E Foy","year":"2005","unstructured":"Foy, E. et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. USA 102, 2986\u20132991 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3184_CR102","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/gut.49.3.423","volume":"49","author":"S Barrett","year":"2001","unstructured":"Barrett, S. et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 49, 423\u2013430 (2001).","journal-title":"Gut"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nm.3184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm.3184","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm.3184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:57:16Z","timestamp":1744289836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":102,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFnm3184"],"URL":"https:\/\/doi.org\/10.1038\/nm.3184","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"9 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.L.T. has served on a scientific advisory board for Gilead and Jansen; his university has received support for his research from Merck and Gilead.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}